Jim Cramer, portfolio manager at Action Alerts PLUS, and research director, Jack Mohr sat down to talk about one of the charitable trust’s newest positions. PayPal (PYPL), a stock which was just spun off from its parent company, eBay (EBAY), ‘is an exciting new name in the portfolio that we’ve been waiting to pounce on,’ Mohr said. Having sold off their position in MasterCard (MA), which Cramer says was a ‘fabulous gain’ for the portfolio, they wanted to get back into the payments space. In 2002 eBay acquired PayPal, which at the time was its own publically traded company. On July 17th of this year, eBay and PayPal officially separated and became two separate, publically traded companies. PayPal shares entered the open markets on that following Monday, July 20th for $41.46 a share. PayPal was founded back in 1998 in Palo Alto, California by Telsa (TSLA) head, Elon Musk and venture capitalist, Peter Thiel among others. Mohr says that PayPal ‘is a marriage of technology and payments’ and Cramer calls it ‘the millennials credit card.’ Cramer also said that PayPal has made a lot of good acquisitions, were given a lot of cash by eBay, and ‘they can build up a franchise that I think will end up rivaling Visa and MasterCard.’
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.